

PRODUCT INFORMATION




BIBF 1120 (esylate)

Item No. 31082

CAS Registry No.: 656247-18-6
Formal Name: (3Z)-2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indole-6-carboxylic acid, methyl ester, monoethanesulfonate

Synonym: Nintedanib
MF: C₃₁H₃₃N₅O₄ • C₂H₆O₃S
FW: 649.8
Purity: ≥98%
UV/Vis.: λ_{max}: 287, 392 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BIBF 1120 (esylate) is supplied as a solid. A stock solution may be made by dissolving the BIBF 1120 (esylate) in the solvent of choice, which should be purged with an inert gas. BIBF 1120 (esylate) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of BIBF 1120 (esylate) in these solvents is approximately 5 and 3 mg/ml, respectively.

BIBF 1120 (esylate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BIBF 1120 (esylate) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. BIBF 1120 (esylate) has a solubility of approximately 0.16 mg/ml in a 1:5 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

BIBF 1120 is an inhibitor of the receptor tyrosine kinases VEGFR, FGFR, and PDGFR (IC₅₀s = 13-34, 37-610, 59, and 65 nM for VEGFR1-3, FGFR1-4, PDGFR α , and PDGFR β , respectively).¹ It is selective for VEGFR, FGFR, and PDGFR over a panel of 33 kinases but does inhibit FLT3, LCK, LYN, and Src (IC₅₀s = 16-156 nM). BIBF 1120 inhibits growth factor-dependent proliferation of human umbilical vascular endothelial cells (HUVECs), human microvascular skin endothelial cells (HSMECs), human umbilical artery smooth muscle cells (HUASMCs), and bovine retinal pericytes (BRPs; EC₅₀s = 7-290 nM). *In vivo*, BIBF 1120 (100 mg/kg) reduces tumor microvessel density and the number of PDGFR β -expressing perivascular cells in a FaDu head and neck small cell carcinoma mouse xenograft model. It also inhibits tumor growth in a Caki-1 renal cancer mouse xenograft model. Formulations containing BIBF 1120 have been used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer (NSCLC).

Reference

1. Hilberg, F., Roth, G.J., Krssak, M., *et al.* BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. *Cancer Res.* **68(12)**, 4774-4782 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/12/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM